This article has been updated from a previous version.
NEW YORK, April 12 – In an apparent twist of fate, beleaguered DoubleTwist said Thursday it has signed up over 20 new subscribers to its online suite of genomic data and analysis tools during the first quarter of 2001.
"This subscription activity is consistant with the company's growth over the past year," Robert Williamson, DoubleTwist president, told GenomeWeb. "We have recently come out of a long quiet period and therefore are now able to share the company's progress with the public. You will be hearing more good news from us."
In March, the company cancelled its initial public offering, and laid off 20 employees, or about 10 percent of its staff. As of September, the company had just $24 million in cash.
The deals, however, should help the company to shore up its dwindling resources.
While DoubleTwist’s basic online subscription is free, customers must purchase licenses to gain access to DoubleTwist’s databases, including its annotated human genome and its gene indices, as well as analysis and visualization tools. The new subscribers are all paying for access to DoubleTwist’s databases, according to a company spokeswoman.
"The vast majority of these subscriptions are at the Gold level, meaning the level at which you access our Annotated Human Genome Database as well as our Gene Indices," said spokeswoman Nicole Litchfield. "Our Silver level is access to to the Gene Indices only, and that represents a fraction of the subscriptions. "
DoubleTwist’s new subscribers include Affibody, Beth Israel Deaconess Medical Center, Taiwan's Biomedical Engineering Center, Boystown National Research Hospital, Celgene, Cureon, Evotec, Ferring Research Institute, GPC Biotech, ImClone Systems, Immusol, H. Lundbeck, Neurogenetics, ONO Pharmaceutical, OSI Pharmaceuticals, PPD Discovery, Hoffmann-La Roche, the University of Minnesota, the University of Tokyo, Xenoport, and an unnamed European pharmaceutical company.